2 nd International Conference on Hematology & Blood Disorders （ Sep. 29-Oct. 01, 2014 Baltimore, USA ） Hyogo College of Medicine Graft-versus-GVHD, a second.

Slides:

Advertisements

Similar presentations

Cancer 101 Monica Schlatter, RN, ND, AOCNP. Types of Cancer AIDS- related malignancies AIDS- related malignancies Bone and soft tissue sarcoma Bone and.

Advertisements

A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.

Bone Marrow Transplant in Oncology

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.

Jeffrey Schriber, M.D. FRCP (c) Medical Director Cancer Transplant Institute Virginia G. Piper Cancer Center Everything You Ever Wanted to Know About Transplant.

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Doug Brutlag Professor Emeritus of.

The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.

Allogeneic Stem Cell Transplantation: The Journey

Hematopoietic Stem Cell Transplant

Introduction to Haematopoietic Stem Cell Transplantation (HSCT) Covenant Health System HSCT Program Lubbock, Texas April 4, 2007.

New Strategies for the Prevention and Treatment of Graft vs. Host Disease (GVHD) Simrit Parmar, MD Stem Cell Transplant & Cellular Therapy BTG2013, Hong.

Graft vs Host Disease Remains the major cause of treatment related morbidity and mortality in allogeneic HCT. Caused by donor derived alloreactive T cells.

What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

Allogeneic “Mini” Transplantation Mark B. Juckett M.D. June 4, 2004.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

G. S / AIH 2006 Graft-versus-Host disease Physiopathology Gérard Socié, MD PhD Hospital Saint Louis Translating experimental into clinical knowledge.

Tolerance Induction Dr. S. Strober Stanford University.

BENIN BLOOD & MARROW TRANSPLANT SOCIETY OF NIGERIA JULY STEM CELL TRANSPLANT CENTRE, BENIN Graft versus Host Disease in HSCT Anthony Oyekunle.

Bone marrow Transplant in Paediatric Haematology

Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.

G. S / AIH 2006 Graft-versus-Host disease Physiopathology III a) T-Cell migration.

Transplantation Prof. Zahid Shakoor College of Medicine King Saud University.

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

HAPLOIDENTICAL STEM CELL TRANSPLANT

Pavan Kumar Bhamidipati 1, John F. DiPersio 1, Keith Stockerl-Goldstein 1, Geoffrey L. Uy 1, Peter Westervelt 1, Feng Gao 2, Ravi Vij 1, Mark A. Schroeder.

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies.

Bone Marrow Transplant

Stem Cell Transplantation

Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.

Heather J. Symons, Moshe Y

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,

Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact.

Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results.

Human Health and Disease

Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings

Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.

Umbilical Cord Blood as an Alternative Source of Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Epstein-Barr Virus–Associated T.

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.

A New Strategy for Treatment of Autoimmune Diseases in Chimeric Resistant MRL/lpr Mice by Kenji Takeuchi, Muneo Inaba, Shigeo Miyashima, Ryokei Ogawa,

Patient charactaristics:

Whom should you refer for allogeneic transplantation?

The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.

CombinationTreatment

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

by Oleg I. Krijanovski, Geoffrey R. Hill, Kenneth R

Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.

Introduction Case Report Conclusion

Figure 2 Components of each transplantation platform

Letermovir(Prevymis™) Guidelines for Inpatient Use

Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

Reduced Intensity Allograft Scopes and Limitations

Short title / Key scientific finding

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Stem Cell Transplant for Myeloid Neoplasms

Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect Shawn G Clouthier,

Bridge to transplant following Bv+Bs regimen.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Frédéric Baron, Rainer Storb

by Lapo Alinari, and Kristie A. Blum

Presentation transcript:

2 nd International Conference on Hematology & Blood Disorders （ Sep. 29-Oct. 01, 2014 Baltimore, USA ） Hyogo College of Medicine Graft-versus-GVHD, a second transplantation from another donor for the rescue from refractory acute GVHD Kazuhiro Ikegame

liver gut skin joint muscle DNA Self-reactive lymphocytes Donor lymphocyte Autoimmune GVHD alloreactive cell therapy nerve Graft-versus-Autoimmunity (GVA) Graft-versus-GVHD (GvGVHD) Concept of Graft-versus-GVHD (GvGVHD)

alloBMT Days after transplantation WBC(x10 6 /l) Plts(x10 6 /l) skin rash WBC Plts MMF FLU+CY+TBI ATGMTX BM relapse on day 144 after 2 nd autoPBSCT ALG 8mg/kg Autologous PBSCT for severe GVHD diarrhea hemorrhagic cystitis mPSL TBI 2Gy TT 10mg/kg autoPBSCT tacrolimus Taniguchi Y, et al. Haematologica. 2003; 88.

Bone Marrow Transplantation (2004) 34, 995–998 Case reports of autologous PBSCT for GVHD

1st BMT ( b / d )2nd BMT ( b / k ) 2weeks BM 1×10 7 spleen 3×10 7 Recipient ( b / k ） TBI 8.5Gy ( B6C3F1) ( BDF1)(B6C3F1) TBI 0, 2, 3, 4, 5 Gy BM 1×10 7 spleen 3×10 7 AutoSCT for GVHD (mouse model) Taniguchi Y, et al. Exp Hematol. 2008; 36:1216.

2 nd SCT B6C3F1→(B6C3F1→B6C3F1) B6C3F1→(BDF1→B6C3F1) TBI 4Gy B6C3F1→(BDF1→B6C3F1) TBI 5Gy TBI toxicity BDF1→B6C3F1 TBI 3Gy BDF1→B6C3F1 GVHD B6C3F1→(BDF1→B6C3F1) TBI 3Gy TBI BDF1→B6C3F1 TBI 3Gy B6C3F1→(BDF1→B6C3F1) TBI 3Gy B6C3F1→(BDF1→B6C3F1) TBI 4Gy B6C3F1→(B6C3F1→B6C3F1) GVHD

Problems of AutoSCT for GVHD 1) Difficult to engraft （ GVH clones are rejecting clones ） 2) Risk of relapse （ Loss of GVL effect ） B6C3F1 (b/k) normal tissue B6C3F1 (b/k) stem cells B6C3F1 (b/k) leukemic cells B6C3F1 (b/k) leukemic cells BDF1 (b/d) lymphocytes k k k k k k b b b b bb b b b b d d d d GVL GVHD Rejection No GVL

第 17 回クリニカルヘマトオンコロジー 5/14/2010 Allogeneic is better than autologous for severe GVHD?

1st BMT ( b / d )2nd BMT ( b / s ) 1, 2, 3 weeks BM 1×10 7 spleen 3×10 7 Recipient ( b / k ） TBI 8.5Gy ( B6C3F1) ( BDF1)(B6B10F1) TBI 0, 2, 3, 4, 5 Gy BM 1×10 7 spleen 3×10 7 AlloSCT for GVHD (mouse model)

Experiment SCT sequence TBI dose For 2 nd SCT Day 7Day 14 Improvement in GVHD score 3Gy 4Gy 3Gy ± ± ± ± ± ± ± ± ± ± ± ± ± T cell chimerism of 1 st and 2 nd donors after 2 nd SCT 3Gy is not enough when GVHD clones are rejecting clones TBI is indispensable in homo-to-hetero (hybrid resistance?) B6C3F1→(BDF1→B6C3F1) B6C3F1→(BDF1→B6C3F1) B6B10F1→(BDF1→B6C3F1) B6B10F1→(BDF1→B6C3F1) C3DF1→(BDF1→B6C3F1) DBA/2→(BDF1→B6C3F1) DBA/2→(BDF1→B6C3F1) ± b/kb/db/k b/db/k b/sb/db/k b/sb/db/k d/kb/db/k d/db/db/k d/db/db/k 2 nd donor chimerism

Human is more important than mouse?

Recovery from established graft-vs- host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Taniguchi Y, et al. Exp Hematol Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. Ikegame K, et al. Exp Hematol Second SCT for refractory acute GVHD from another haploidentical donor (n=15 cases) Engraftment 11, rejection 4 53% in engraftment cases, early death of GVHD in all rejected cases Mouse model Clinical Graft-versus-GVHD

FLU30mg/m 2 ATG F 2mg/kg day Tacrolimus civ (9-11ng/ml) mPSL 1mg/kg PBSCT TBI3Gy Representative regimen of GvGVHD

skin gut liver No. 1 No. 4 No. 5 No. 6 No. 8 No. 9 Change of GVHD stage along time course before and after GvGVHD in engrafted cases 0-100

Patients with complete response (%) Response and survival after GvGVHD engraftment rejection engraftment rejection

Fujioka (SB) Okada (CB) Taniguchi K (FW) Ikegame (MF) Inoue (graduate student) Lineup of HCM (Acknowlegement) Ward (clinical) Lab. (research) (Coach) Kato (graduate student) Soma (GK) Ishi (FW) Kaida (FW) Yoshihara (MF) Taniguchi Y (SB) NursesDoctors Pain control team Clinical psychiatrists pharmacists PT Tamaki (CB)